Enzyme’s role in cancer-causing mutations

An enzyme could be responsible for two mutational signatures found in cancers in the small intestine, according to the first study of its kind.

In the first comprehensive study of somatic mutations in normal human small intestine, a team from the Wellcome Sanger institute discovered that the APOBEC1 enzyme may be responsible for two mutational signatures, SBS2 and SBS13.

Writing in today’s edition of Nature Genetics, the authors say because APOBEC1 performs a vital role in nutrient absorption in the small intestine, high levels of SBS2 and SBS13 in the small intestine may be “collateral damage” caused by the normal functioning of cells.

APOBEC is a family of enzymes that edit DNA or RNA2, and mutations caused by the activity of these enzymes are common in many human cancers.

Researchers set out to characterise the mutational landscape of the small intestine and completed whole genome sequences of 342 individual small intestine crypts from 39 individuals.

Analysis of somatic mutations in these tissues identified three mutational signatures found in most normal human cells: SBS1, SBS5 and SBS18. However, they found mutational signatures SBS2 and SBS13 were also common, which are rare in the large intestine and most other normal tissues.

First study author Yichen Wang, from the Wellcome Sanger Institute, said: “Previous research on the SBS2 and SBS13 mutational signatures in humans has generally focused on APOBEC3A and APOBEC3B.

“However, our findings show that in normal small intestine epithelium, APOBEC1 is the likely culprit. It could be that the high levels of SBS2 and SBS13 in this organ are ‘collateral damage’ caused by the high levels of APOBEC1 present, which are needed for the small intestine to do its normal job of absorbing and transporting nutrients.”

The researcher retraced how each intestinal crypt developed from a single cell into several thousand, which led them to discovering fundamental information about somatic mutation in the small intestine.

Study co-author Dr Philip Robinson, from the Wellcome Sanger Institute and the University of Cambridge, said: “Our analysis reveals that APOBEC mutations occur in small bursts, with a single or very small number of episodes during the lifetime of an individual.

“The earliest instance we found was four years of age. The likely cause of APOBEC mutations in the small intestine seem to be due to circumstances within the cell itself, rather than as a result of an external factor such as genotoxic metabolites produced by bacteria.”

The role these enzymes play and the causal mechanism by which cancer begins to develop remain unclear, but the team says “collateral damage” resulting from normal cell functioning merits further exploration.

Wang Y et al. APOBEC mutagenesis is a common process in normal human small intestine. Nature Genetics 26 January 2023

[abstract]

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index